Interstitial lung diseases (ILDs) are a very heterogeneous group of diseases. Although the aetiology of many of these diseases is not fully understood, an association with specific pathogenic gene variants has been demonstrated for some of the diseases. The aim of this review is to provide genotype-phenotype correlation information on monogenic ILDs to provide guidance to pulmonologists on when to refer ILD patients for genetic testing. Most patients with monogenic ILDs suffer from multiorgan involvement and should be managed by a multidisciplinary team of specialists. Different syndromes are associated with a greater risk of (nonrespiratory) malignancies (Birt-Hogg-Dubé syndrome and telomeropathies). Isolated lung involvement has been described in surfactant-related gene variant carriers (SFTPA 1 and 2, SFTPC) and patients with pulmonary alveolar microlithiasis. The clinical suspicion of monogenic ILDs should be raised in young patients diagnosed with ILD, patients with a known family history of ILD or suspected telomeropathies, and patients suspected of having syndromes associated with ILD. Patients with suspected monogenic ILDs should be aware of the possibility of genetic counselling both to obtain a diagnosis and to select further follow-up by pulmonologists and other involved specialists. Raising awareness of monogenic ILDs and creating counselling platforms is necessary both to diagnose and manage patients with these rare diseases.

Department of Internal Hematology and Oncology University Hospital Brno and Medical Faculty of Masaryk University Brno Czech Republic

Department of Respiratory Medicine and Tuberculosis University Hospital Brno and Medical Faculty of Masaryk University Brno Czech Republic

Department of Respiratory Medicine Thomayer University Hospital and 1st Medical Faculty of Charles University Prague Czech Republic

Department of Respiratory Medicine University Hospital Motol and 2nd Medical Faculty of Charles University Prague Czech Republic

Institute of Biology and Clinical Genetics University Hospital Motol and 2nd Medical Faculty of Charles University Prague Czech Republic

Zobrazit více v PubMed

American Thoracic Society , European Respiratory Society . American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304. doi: 10.1164/ajrccm.165.2.ats01 PubMed DOI

Griese M. Etiologic classification of diffuse parenchymal (Interstitial) lung diseases. J Clin Med 2022; 11: 1747. doi: 10.3390/jcm11061747 PubMed DOI PMC

Borie R, Kannengiesser C, de Fontbrune FS, et al. Management of suspected monogenic lung fibrosis in a specialized center. Eur Respir Rev 2017; 26: 160122. doi: 10.1183/16000617.0122-2016 PubMed DOI PMC

Borie R, Kannengiesser C, Antoniou K, et al. European Respiratory Society statement on familial pulmonary fibrosis. Eur Respir J 2023; 61: 2201383. doi: 10.1183/13993003.01383-2022 PubMed DOI

Grenier PA, Brun AL, Longchampt E, et al. Primary immunodeficiency diseases of adults: a review of pulmonary complication imaging findings. Eur Radiol 2024; 34: 4142–4154. doi: 10.1007/s00330-023-10334-7 PubMed DOI PMC

Deniz O, Ors F, Tozkoparan E, et al. High resolution computed tomographic features of pulmonary alveolar microlithiasis. Eur J Radiol 2005; 55: 452–460. doi: 10.1016/j.ejrad.2005.01.010 PubMed DOI

Diesler R, Legendre M, Si-Mohamed S, et al. Similarities and differences of interstitial lung disease associated with pathogenic variants in SFTPC and ABCA3 in adults. Respirology 2024; 29: 312–323. doi: 10.1111/resp.14667 PubMed DOI

Velázquez-Díaz P, Nakajima E, Sorkhdini P, et al. Hermansky-pudlak syndrome and lung disease: pathogenesis and therapeutics. Front Pharmacol 2021; 12: 644671. doi: 10.3389/fphar.2021.644671 PubMed DOI PMC

Franciosi AN, Gupta N, Murphy DJ, et al. Diffuse cystic lung disease: a clinical guide to recognition and management. Chest 2025; 167: 529–547. doi: 10.1016/j.chest.2024.08.008 PubMed DOI

Buschulte K, Cottin V, Wijsenbeek M, et al. The world of rare interstitial lung diseases. Eur Respir Rev 2023; 32: 220161. doi: 10.1183/16000617.0161-2022 PubMed DOI PMC

Courtwright AM, El-Chemaly S. Telomeres in interstitial lung disease: the short and the long of it. Ann Am Thorac Soc 2019; 16: 175–181. doi: 10.1513/AnnalsATS.201808-508CME PubMed DOI PMC

Schinella RA, Greco MA, Garay SM, et al. Hermansky–Pudlak syndrome: a clinicopathologic study. Hum Pathol 1985; 16: 366–376. doi: 10.1016/S0046-8177(85)80230-6 PubMed DOI

van Moorsel CHM, van der Vis JJ, Grutters JC. Genetic disorders of the surfactant system: focus on adult disease. Eur Respir Rev 2021; 30: 200085. doi: 10.1183/16000617.0085-2020 PubMed DOI PMC

McCarthy C, Gupta N, Johnson SR, et al. Lymphangioleiomyomatosis: pathogenesis, clinical features, diagnosis, and management. Lancet Respir Med 2021; 9: 1313–1327. doi: 10.1016/S2213-2600(21)00228-9 PubMed DOI

Dhalla F, Lochlainn DJM, Chapel H, et al. Histology of interstitial lung disease in common variable immune deficiency. Front Immunol 2020; 11: 605187. doi: 10.3389/fimmu.2020.605187 PubMed DOI PMC

Castellana G, Castellana G, Gentile M, et al. Pulmonary alveolar microlithiasis: review of the 1022 cases reported worldwide. Eur Respir Rev 2015; 24: 607–620. doi: 10.1183/16000617.0036-2015 PubMed DOI PMC

Dardis A, Michelakakis H, Rozenfeld P, et al. Patient centered guidelines for the laboratory diagnosis of Gaucher disease type 1. Orphanet J Rare Dis 2022; 17: 442. doi: 10.1186/s13023-022-02573-6 PubMed DOI PMC

Doubková M, Staňo Kozubík K, Radová L, et al. A novel germline mutation of the PubMed DOI PMC

Klay D, Grutters JC, van der Vis JJ, et al. Progressive disease with low survival in adult patients with pulmonary fibrosis carrying surfactant-related gene mutations: an observational study. Chest 2023; 163: 870–880. doi: 10.1016/j.chest.2022.11.002 PubMed DOI

Legendre M, Butt A, Borie R, et al. Functional assessment and phenotypic heterogeneity of PubMed DOI

Brudon A, Legendre M, Mageau A, et al. High risk of lung cancer in surfactant-related gene variant carriers. Eur Respir J 2024; 63: 2301809. doi: 10.1183/13993003.01809-2023 PubMed DOI PMC

Li Y, Seidl E, Knoflach K, et al. ABCA3-related interstitial lung disease beyond infancy. Thorax 2023; 78: 587–595. doi: 10.1136/thorax-2022-219434 PubMed DOI PMC

Borie R, Funalot B, Epaud R, et al. PubMed DOI PMC

Savage SA, Niewisch MR. Dyskeratosis congenita and related telomere biology disorders. PubMed

Alder JK, Armanios M. Telomere-mediated lung disease. Physiol Rev 2022; 102: 1703–1720. doi: 10.1152/physrev.00046.2021 PubMed DOI PMC

George G, Rosas IO, Cui Y, et al. Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease. Chest 2015; 147: 1549–1557. doi: 10.1378/chest.14-0631 PubMed DOI PMC

Newton CA, Batra K, Torrealba J, et al. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 2016; 48: 1710–1720. doi: 10.1183/13993003.00308-2016 PubMed DOI PMC

Revy P, Kannengiesser C, Bertuch AA. Genetics of human telomere biology disorders. Nat Rev Genet 2023; 24: 86–108. doi: 10.1038/s41576-022-00527-z PubMed DOI

Geilswijk M, Genuardi M, Woodward ER, et al. ERN GENTURIS clinical practice guidelines for the diagnosis, surveillance and management of people with Birt-Hogg-Dubé syndrome. Eur J Hum Genet 2024; 32: 1542–1550. doi: 10.1038/s41431-024-01671-2 PubMed DOI PMC

Daccord C, Good JM, Morren MA, et al. Birt-Hogg-Dubé syndrome. Eur Respir Rev 2020; 29: 200042. doi: 10.1183/16000617.0042-2020 PubMed DOI PMC

Zhang H, Andreou A, Bhatt R, et al. Characteristics, etiology and implications for management of multiple primary renal tumors: a systematic review. Eur J Hum Genet 2024; 32: 887–894. doi: 10.1038/s41431-024-01628-5 PubMed DOI PMC

Northrup H, Aronow ME, Bebin EM, et al. ; International tuberous sclerosis complex consensus group. updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021; 123: 50–66. doi: 10.1016/j.pediatrneurol.2021.07.011 PubMed DOI

Northrup H, Koenig MK, Pearson DA, et al. Tuberous sclerosis complex. PubMed

Rebaine Y, Nasser M, Girerd B, et al. Tuberous sclerosis complex for the pulmonologist. Eur Respir Rev 2021; 30: 200348. doi: 10.1183/16000617.0348-2020 PubMed DOI PMC

Alves Júnior SF, Zanetti G, Alves de Melo AS, et al. Neurofibromatosis type 1: State-of-the-art review with emphasis on pulmonary involvement. Respir Med 2019; 149: 9–15. doi: 10.1016/j.rmed.2019.01.002 PubMed DOI

Zamora AC, Collard HR, Wolters PJ, et al. Neurofibromatosis-associated lung disease: a case series and literature review. Eur Respir J 2007; 29: 210–214. doi: 10.1183/09031936.06.00044006 PubMed DOI

Introne WJ, Huizing M, Malicdan MCV, et al. Hermansky–Pudlak syndrome. PubMed

Doubková M, Trizuljak J, Vrzalová Z, et al. Novel genetic variant of HPS1 gene in Hermansky–Pudlak syndrome with fulminant progression of pulmonary fibrosis: a case report. BMC Pulm Med 2019; 19: 178. doi: 10.1186/s12890-019-0941-4 PubMed DOI PMC

Vicary GW, Vergne Y, Santiago-Cornier A, et al. Pulmonary fibrosis in Hermansky–Pudlak syndrome. Ann Am Thorac Soc 2016; 13: 1839–1846. PubMed PMC

Yokoyama T, Gochuico BR. Hermansky–Pudlak syndrome pulmonary fibrosis: a rare inherited interstitial lung disease. Eur Respir Rev 2021; 30: 200193. doi: 10.1183/16000617.0193-2020 PubMed DOI PMC

Borie R, Crestani B, Guyard A, et al. Interstitial lung disease in lysosomal storage disorders. Eur Respir Rev 2021; 30: 200363. doi: 10.1183/16000617.0363-2020 PubMed DOI PMC

McGovern MM, Wasserstein MP, Bembi B, et al. Prospective study of the natural history of chronic acid sphingomyelinase deficiency in children and adults: eleven years of observation. Orphanet J Rare Dis 2021; 16: 212. doi: 10.1186/s13023-021-01842-0 PubMed DOI PMC

Tirelli C, Rondinone O, Italia M, et al. The genetic basis, lung involvement, and therapeutic options in Niemann–Pick disease: a comprehensive review. Biomolecules 2024; 14: 211. doi: 10.3390/biom14020211 PubMed DOI PMC

Krone KA, Winant AJ, Vargas SO, et al. Pulmonary manifestations of immune dysregulation in CTLA-4 haploinsufficiency and LRBA deficiency. Pediatr Pulmonol 2021; 56: 2232–2241. doi: 10.1002/ppul.25373 PubMed DOI

Fabre A, Marchal S, Barlogis V, et al. Clinical aspects of STAT3 gain-of-function germline mutations: a systematic review. J Allergy Clin Immunol Pract 2019; 7: 1958–1969.e9. doi: 10.1016/j.jaip.2019.02.018 PubMed DOI

Maccari ME, Wolkewitz M, Schwab C, et al. Activated phosphoinositide 3-kinase δ syndrome: update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity. J Allergy Clin Immunol 2023; 152: 984–996.e10. doi: 10.1016/j.jaci.2023.06.015 PubMed DOI

Gilje EA, Abbott JK. The pulmonary effects of STAT3 deficiency. J Allergy Clin Immunol 2023; 152: 368–370. doi: 10.1016/j.jaci.2023.06.003 PubMed DOI

Griese M, Zarbock R, Costabel U, et al. GATA2 deficiency in children and adults with severe pulmonary alveolar proteinosis and hematologic disorders. BMC Pulm Med 2015; 15: 87. doi: 10.1186/s12890-015-0083-2 PubMed DOI PMC

Svobodova T, Mejstrikova E, Salzer U, et al. Diffuse parenchymal lung disease as first clinical manifestation of GATA-2 deficiency in childhood. BMC Pulm Med 2015; 15: 8. doi: 10.1186/s12890-015-0006-2 PubMed DOI PMC

Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med 2014; 371: 507–518. doi: 10.1056/NEJMoa1312625 PubMed DOI PMC

Kim HR, Lim SH, Park JS, et al. Unraveling the diagnostic odyssey: stimulator of interferon gene-associated vasculopathy with onset in infancy in a 30-year-old female. J Rheum Dis 2024; 31: 182–187. doi: 10.4078/jrd.2023.0075 PubMed DOI PMC

Cetin Gedik K, Lamot L, Romano M, et al. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory Type I interferonopathies: CANDLE/PRAAS, SAVI, and AGS. Arthritis Rheumatol 2022; 74: 735–751. doi: 10.1002/art.42087 PubMed DOI

Tsui JL, Estrada OA, Deng Z, et al. Analysis of pulmonary features and treatment approaches in the COPA syndrome. ERJ Open Res 2018; 4: 00017-2018. doi: 10.1183/23120541.00017-2018 PubMed DOI PMC

Jönsson ÅLM, Hilberg O, Simonsen U, et al. New insights in the genetic variant spectrum of SLC34A2 in pulmonary alveolar microlithiasis; a systematic review. Orphanet J Rare Dis 2023; 18: 130. doi: 10.1186/s13023-023-02712-7 PubMed DOI PMC

Hoeger PH, Koehler LM, Reipschlaeger M, et al. Hereditary fibrosing poikiloderma (POIKTMP syndrome) report of a new mutation and review of the literature. Pediatr Dermatol 2023; 40: 182–187. doi: 10.1111/pde.15133 PubMed DOI

Mercier S, Küry S, Salort-Campana E, et al. Expanding the clinical spectrum of hereditary fibrosing poikiloderma with tendon contractures, myopathy and pulmonary fibrosis due to FAM111B mutations. Orphanet J Rare Dis 2015; 10: 135. doi: 10.1186/s13023-015-0352-4 PubMed DOI PMC

Hartmannová H, Piherová L, Tauchmannová K, et al. Acadian variant of Fanconi syndrome is caused by mitochondrial respiratory chain complex I deficiency due to a noncoding mutation in complex I assembly factor NDUFAF6. Hum Mol Genet 2016; 25: 4062–4079. doi: 10.1093/hmg/ddw245 PubMed DOI

Beck DB, Ferrada MA, Sikora KA, et al. Somatic mutations in PubMed DOI PMC

Borie R, Debray MP, Guedon AF, et al. Pleuropulmonary manifestations of vacuoles, E1 Enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome. Chest 2023; 163: 575–585. doi: 10.1016/j.chest.2022.10.011 PubMed DOI

Casal Moura M, Baqir M, Tandon YK, et al. Pulmonary manifestations in VEXAS syndrome. Respir Med 2023; 213: 107245. doi: 10.1016/j.rmed.2023.107245 PubMed DOI